Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 21 June 2022, 23:45 HKT/SGT
Share:
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead(TM) Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium

Gaithersburg, MD, USA and Suzhou BioBay, China, June 21, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead(TM) technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtually on June 22-24, 2022.

Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead(TM), relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA(TM) (miniaturized RNAi triggers) and muRNA(TM) (multi-unit RNAi triggers). mxRNAs(TM) are comprised of single ~30 nt long oligonucleotides to downregulate individual genes, while muRNA(TM) molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously. Sirnaomics will present data at the Symposium evaluating these two technologies, especially the muRNA molecule that has been validated in an animal model for its dual-targeted gene silencing activity, and a progress report on the quickly expanding GalAhead(TM) therapeutic pipeline.

Presentation Details
-- Presentation Title: GalAhead(TM): a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
-- Presenter: Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics
-- Date: June 22-24, 2022 (The presentation will be pre-recorded and available on demand)
-- Location: Online via the Symposium website

"Sirnaomics is striving to develop RNAi delivery technology for effective therapeutic application. Our novel GalAhead(TM) technology has been repeatedly validated with both single-targeted and dual-targeted RNAi therapeutics using rodents and non-human primate animal models," said Dr. Patrick Lu, founder, chairman of the Board, Executive Director, President and CEO of Sirnaomics. "We are expecting expanded clinical testing for our GalAhead(TM) platform and RNAi drug candidates for several liver metabolic diseases in 2023."

"Since we introduced GalAhead(TM) in 2019, the technology has continuously proved to be both robust and reproducible," said Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics. "Based on this progress, we will have our first therapeutic candidate filed for IND approval by the end of 2022. This year, we have already nominated four more GalAhead(TM) based developmental candidates, including the first double-targeting molecule, and are planning to add more by the end of the year."

For more information about Sirnaomics' presentation, please visit the event website at https://www.umassmed.edu/RNATx/.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Dmitry Samarsky, PhD
Chief Technology Officer, Sirnaomics
Email: DmitrySamarsky@sirnaomics.com

Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com




Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Moonstake Now Supports Staking of ORBS on Polygon Network  
July 4, 2022 10:38 HKT/SGT
Ausnutria: Adjusted Channel Strategies in Response to Market Changes and Committed to Long-Term Development  
July 4, 2022 09:07 HKT/SGT
How Technology Contributes to Economical Gaps in Southeast Asia   
July 4, 2022 08:00 HKT/SGT
Indonesian peace mission on Russia-Ukraine conflict  
July 3, 2022 21:00 HKT/SGT
IBO Technology Achieves Turnaround in FY2021/22 Annual Results   
July 3, 2022 17:15 HKT/SGT
Indonesia recommends Energy Transition Policies at B20 ESC Meeting  
July 1, 2022 20:00 HKT/SGT
Asia-Pacific housing stakeholders' call to 'build forward better' continues at World Urban Forum, Poland  
July 1, 2022 18:08 HKT/SGT
PLS Plantations appoints Lee Hun Kheng as Group CEO to advance business transformation  
July 1, 2022 16:00 HKT/SGT
Mitsubishi Corporation: Seven-Member Partnership Commits to Warehouse DX Initiative  
Friday, July 1, 2022 3:10:00 PM
NEC Expands Global Solutions Delivery Capacity with Acquisition of Aspire Technology, a Network Solutions and System Integration Company  
Friday, July 1, 2022 11:47:00 AM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: